PMID- 32043244
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20210730
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 20
IP  - 5
DP  - 2020 Oct
TI  - Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease 
      Prevention.
PG  - 419-429
LID - 10.1007/s40256-020-00397-y [doi]
AB  - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
      patients with type 2 diabetes mellitus (T2DM). Because of these associated risks, 
      managing diabetes and CVD, including heart failure (HF), has become a joint 
      effort to reduce the risk of adverse outcomes. Although many patients with T2DM 
      are receiving preventive therapies for CVD, their residual risk remains high for 
      atherosclerotic CVD (ASCVD). Recent data regarding the use of antidiabetic 
      medications to prevent negative cardiovascular outcomes has revealed a positive 
      association with reduced major adverse cardiovascular events (MACE). One class of 
      medications, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, are at the 
      forefront of the cardiovascular outcomes prevention discussion. The clinical data 
      presented in this review indicate the potential cardiovascular benefits of SGLT-2 
      inhibitors in patients with CVD and its potential value as a treatment option in 
      preventing CVD in various patient populations.
FAU - Reid, Jessica
AU  - Reid J
AD  - East Coast Institute for Research, 3550 University Blvd. South, Suite 101, 
      Jacksonville, FL, 32216, USA.
AD  - University of Florida College of Pharmacy, Jacksonville, FL, USA.
FAU - Rana, Khyatiben
AU  - Rana K
AD  - East Coast Institute for Research, 3550 University Blvd. South, Suite 101, 
      Jacksonville, FL, 32216, USA.
FAU - Niman, Stephanie
AU  - Niman S
AD  - East Coast Institute for Research, 3550 University Blvd. South, Suite 101, 
      Jacksonville, FL, 32216, USA.
FAU - Sheikh-Ali, Mae
AU  - Sheikh-Ali M
AD  - Northeast Florida Endocrine and Diabetes Associates, Jacksonville, FL, USA.
FAU - Lewis, Todd
AU  - Lewis T
AD  - Baker-Gilmour Cardiovascular Institute, Jacksonville, FL, USA.
FAU - Choksi, Rushab R
AU  - Choksi RR
AD  - East Coast Institute for Research, 3550 University Blvd. South, Suite 101, 
      Jacksonville, FL, 32216, USA.
FAU - Goldfaden, Rebecca F
AU  - Goldfaden RF
AD  - East Coast Institute for Research, 3550 University Blvd. South, Suite 101, 
      Jacksonville, FL, 32216, USA. Rebecca.Goldfaden@ecirmed.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Cardiometabolic Risk Factors
MH  - *Cardiovascular Diseases/epidemiology/prevention & control
MH  - Comorbidity
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology
MH  - Sodium-Glucose Transporter 2 Inhibitors/*pharmacology
EDAT- 2020/02/12 06:00
MHDA- 2021/07/31 06:00
CRDT- 2020/02/12 06:00
PHST- 2020/02/12 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
PHST- 2020/02/12 06:00 [entrez]
AID - 10.1007/s40256-020-00397-y [pii]
AID - 10.1007/s40256-020-00397-y [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2020 Oct;20(5):419-429. doi: 10.1007/s40256-020-00397-y.